InMed Pharmaceuticals (INM) investors approve directors, auditor and 20%+ SEPA share issuance

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. reported the results of its 2025 Annual General and Special Meeting of Shareholders held on December 17, 2025. Shareholders elected five directors – Eric A. Adams, Andrew Hull, Nicole Lemerond, Neil Klompas and John Bathery – each receiving between 81.94% and 82.11% of votes cast in favor.

Shareholders also approved the appointment of CBIZ CPAs P.C as InMed’s independent registered public accounting firm until the 2026 annual meeting, with 78.84% of votes for and 21.16% abstaining. A key item, the SEPA Share Issuance Proposal, passed with 65.89% support and 34.11% against, authorizing the potential issuance of 20% or more of the company’s common shares outstanding as of December 13, 2024 under a Standby Equity Purchase Agreement with YA II PN, Ltd., in accordance with Nasdaq Listing Rules 5635(d) and 5635(b). No other matters were voted on.

Insights

Corporate governance and capital markets analyst

Shareholders backed all board and auditor proposals and approved a sizeable potential equity issuance under an existing purchase agreement.

The meeting confirmed board and oversight stability at InMed Pharmaceuticals Inc., with all five director nominees elected on vote support just above 82%. The reappointment of CBIZ CPAs P.C as independent registered public accounting firm, with 783,232 votes for and 78.84% support, indicates broad acceptance of current audit arrangements despite a notable abstain bloc.

The most financially significant item was the approval of the SEPA Share Issuance Proposal. Shareholders authorized the potential issuance of 20% or more of common shares outstanding as of December 13, 2024 under the Standby Equity Purchase Agreement with YA II PN, Ltd., as amended on June 13, 2025, to comply with Nasdaq Listing Rules 5635(d) and 5635(b). The vote, with 100,693 for (65.89%) and 52,128 against (34.11%), shows meaningful but not overwhelming support, reflecting awareness that any substantial future drawdowns under this facility could expand the share count and influence ownership percentages depending on how it is used.

8-K Event Classification

3 items: 5.07, 7.01, 9.01

3 items

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 2025-12-17 0001728328 InMed Pharmaceuticals Inc. 0001728328 2025-12-17 2025-12-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 17, 2025

INMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

British Columbia	001-39685	98-1428279
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

Suite 1445 – 885 West Georgia Street
Vancouver, British Columbia, Canada V6C 3E8
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (604) 669-7207

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07: Submission of Matters to a Vote of Security Holders.

On December 17, 2025, InMed Pharmaceuticals Inc. (the "Corporation") held its 2025 Annual General and Special Meeting of Shareholders (the "Meeting").  At the Meeting, all items of business were voted upon by the shareholders, as indicated below:

Proposal No. 1-Presentation of Financial Statements

The Company's audited consolidated financial statements for the fiscal year ended June 30, 2025, including the related management's discussion and analysis and auditors report was presented to shareholders at the Meeting.  No vote was taken with respect to the audited annual financial statements and receipt of the audited annual financial statements did not, and does not, constitute approval or disapproval of any matters referred to therein.

Proposal No. 2-Election of Directors

The Corporation's shareholders approved the election of five director nominees to the Corporation's board of directors (the "Board") to hold office until the 2026 Annual General Meeting of Shareholders or until their successors are elected or appointed.

Results of the vote for the election of the Board at the Meeting are set out as follows:

Director		Votes For						Withheld Votes
		Number			Percentage			Number			Percentage
Eric A. Adams		125,352			82.03%			27,469			17.98%
Andrew Hull		125,315			82.00%			27,506			18.00%
Nicole Lemerond		125,485			82.11%			27,336			17.89%
Neil Klompas		125,444			82.09%			27,377			17.91%
John Bathery		125,227			81.94%			27,594			18.06%

Proposal No. 3-Appointment of Auditor

The Corporation's shareholders voted at the Meeting to approve the appointment of CBIZ CPAs P.C as the independent registered public accounting firm of the Corporation until the 2026 Annual General Meeting of Shareholders or until a successor is named.

Votes For	% Votes For	Votes Against	Votes Abstained	% Votes Abstained1	Broker Non-Votes
783,232	78.84%	0	210,258	21.16%	1

2

Proposal No. 4-SEPA Share Issuance Proposal

Shareholders approved by ordinary resolution the potential issuance of 20% or more of the Corporation's common shares issued and outstanding as of December 13, 2024 pursuant to the Standby Equity Purchase Agreement with YA II PN, Ltd., as amended on June 13, 2025, pursuant to Nasdaq Listing Rules 5635(d) and 5635(b).

Votes For	% Votes For	Vote Against	% Votes Against	Abstain	Broker Non- Votes
100,693	65.89%	52,128	34.11%	0	840,670

Proposal No. 5-Other Business

No other matters came to a vote before the Metting other than as set forth above.

Votes For	% Votes For	Vote Against	% Votes Against	Abstain	Broker Non-Votes
129,408	84.68%	23,414	15.32%	0	840,699

Item 7.01 Regulation FD Disclosure.

On December 18, 2024, the Corporation issued a press release announcing the voting results of the Meeting and other related matters. A copy of the press release is furnished hereto as Exhibit 99.1.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, including, without limitation, any registration statement filed pursuant thereto, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01  Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1.	Press release, dated December 17, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 17, 2025

	INMED PHARMACEUTICALS INC.
	By:	/s/ Eric A. Adams
	Name:	Eric A. Adams
	Title:	Chief Executive Officer

3

FAQ

What did InMed Pharmaceuticals (INM) shareholders approve at the 2025 annual meeting?

At the 2025 Annual General and Special Meeting, InMed Pharmaceuticals Inc. shareholders elected five directors, approved the appointment of CBIZ CPAs P.C as independent registered public accounting firm until the 2026 annual meeting, and passed the SEPA Share Issuance Proposal authorizing the potential issuance of 20% or more of common shares outstanding as of December 13, 2024 under a Standby Equity Purchase Agreement with YA II PN, Ltd.

Which directors were elected to the InMed Pharmaceuticals (INM) board and with what support?

Shareholders elected Eric A. Adams, Andrew Hull, Nicole Lemerond, Neil Klompas and John Bathery to the board to serve until the 2026 annual meeting or until successors are elected or appointed. Support for each ranged from 81.94% of votes cast in favor for John Bathery to 82.11% for Nicole Lemerond, with the balance of votes withheld.

Who is the auditor for InMed Pharmaceuticals (INM) following the 2025 shareholder vote?

Shareholders approved CBIZ CPAs P.C as InMed Pharmaceuticals Inc.’s independent registered public accounting firm until the 2026 Annual General Meeting of Shareholders or until a successor is named. The vote recorded 783,232 votes for (78.84%) and 210,258 votes abstained (21.16%), with no votes against.

What is the SEPA Share Issuance Proposal approved by InMed Pharmaceuticals (INM) shareholders?

The SEPA Share Issuance Proposal authorizes the potential issuance of 20% or more of InMed’s common shares issued and outstanding as of December 13, 2024 pursuant to a Standby Equity Purchase Agreement with YA II PN, Ltd., as amended on June 13, 2025. This approval is given pursuant to Nasdaq Listing Rules 5635(d) and 5635(b).

How did InMed Pharmaceuticals (INM) shareholders vote on the SEPA Share Issuance Proposal?

The SEPA Share Issuance Proposal received 100,693 votes for (65.89%) and 52,128 votes against (34.11%), with no abstentions and 840,670 broker non-votes. This result means the proposal was approved by ordinary resolution.

Were any other business items voted on at the InMed Pharmaceuticals (INM) 2025 meeting?

No. The company states that no other matters came to a vote before the meeting other than the proposals described, which included the financial statement presentation (non-voting), director elections, auditor appointment, the SEPA Share Issuance Proposal, and an item for other business that did not introduce additional voted matters.